Exceptional Responder to Pembrolizumab Guides Immunotherapy Progress in Leiomyosarcoma – OncLive
|
Exceptional Responder to Pembrolizumab Guides Immunotherapy Progress in Leiomyosarcoma
OncLive … Medical School, clinical director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discussed the exceptional responder to pembrolizumab and the significance of these findings for further immunotherapy advances in leiomyosarcoma. |
